General
Keynote speaker: Jennifer Guerreiro
Title lecture: Targeting novel populations of macrophages for breast cancer therapy
Dr. Guerriero is a PhD immunologist and runs an independent laboratory at Brigham and Women’s Hospital (BWH) / Harvard Cancer Center (HCC) that focuses on developing novel strategies to modulate tumor associated macrophages (TAMs). The Guerriero laboratory works on unraveling the complexity of TAM biology, ontogeny and metabolic regulation with the goal of developing clinically effective strategies to target TAMs to promote T-cell activa
tion and weaken the immune-suppressive TME to improve immunotherapy response rates. As a faculty member of the Breast Oncology Program at DFCI Dr. Guerriero leads and supports translational research to investigate innovated methods to modulate the immune response in breast cancer as well as to better understand the mechanistic basis for sensitivity and resistance to currently available immunotherapies.
Dr. Guerriero received a BS in biochemistry from Northeastern University while on a Division I pole vault scholarship. She received a PhD in molecular and cellular biology and immunology and pathology from Stony Brook University. She completed her postdoctoral fellowship at Dana-Farber Cancer Institute and joined the faculty in 2017 as an Instructor, before joining Brigham and Women’s Hospital as an independent investigator in 2020.
Dr. Guerriero currently serves as a Director At-Large for the Society for Immunotherapy of Cancer (SITC) and an AACR Cancer Immunology Working Group Steering Committee member. She is an Associate Editor for the Journal for ImmunoTherapy of Cancer (JITC). Dr. Guerriero is also co-founder of The Myeloid Network, a monthly international seminar series aimed to connect researchers worldwide to promote communication and advancement in the field of myeloid cell biology.
Host: Tanja de Gruijl, Cancer Immunology
AII Seminar on location: 16.00 - 17.00 hrs
This seminar is the last Seminar in our Spring Series, in the Fall our Seminar Series will be resumed.